EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #02696_C
人巨核细胞扩增的无血清培养补充物
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
StemSpan™巨核细胞扩增补充剂（100X）包含重组人细胞因子的组合，用于选择性地促进从人脐带血（CB）或骨髓（BM）样本中分离的CD34+细胞的人巨核细胞祖细胞的扩增和分化。
StemSpan™巨核细胞扩增补充（100X）用于与以下任何StemSpan™培养基结合使用：
•StemSpan™SFEM（目录#09600）
StemSpan™SFEM II（目录#09605）
StemSpan™-XF（目录#100-0073）
StemSpan™-AOF（目录#100-0130）
当添加到无血清培养基中时，StemSpan™巨核细胞扩增补充剂通常促进每个输入CD34+细胞在CD34+人CB细胞启动的14天液体培养中产生数百个巨核细胞。请参阅data选项卡了解更多详细信息。
Contains
• Recombinant human stem cell factor (SCF)
• Recombinant human interleukin 6 (IL-6)
• Recombinant human interleukin 9 (IL-9)
• Recombinant human thrombopoietin (TPO)
Subtype
Supplements
Cell Type
Hematopoietic Stem and Progenitor Cells, Megakaryocytes
Species
Human
Application
Cell Culture, Differentiation, Expansion
Brand
StemSpan
Area of Interest
Stem Cell Biology, Transplantation Research
Formulation Category
Serum-Free
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (7)
文献 (11)
Identification of unipotent megakaryocyte progenitors in human hematopoiesis. Blood 2017 MAR
Abstract
The developmental pathway for human megakaryocytes remains unclear and the definition of pure unipotent megakaryocyte progenitor is still controversial. Using single-cell transcriptome analysis, we have identified a cluster of cells within immature hematopoietic stem and progenitor cell populations that specifically express genes related to the megakaryocyte lineage. We used CD41 as a positive marker to identify these cells within the CD34(+)CD38(+)IL-3Rα(dim)CD45RA(-) common myeloid progenitor (CMP) population. These cells lacked erythroid and granulocyte/macrophage potential, but exhibited robust differentiation into the megakaryocyte lineage at a high frequency, both in vivo and in vitro The efficiency and expansion potential of these cells exceeded those of conventional bipotent megakaryocyte/erythrocyte progenitors. Accordingly, the CD41(+) CMP was defined as a unipotent megakaryocyte progenitor (MegP) that is likely to represent the major pathway for human megakaryopoiesis, independent of canonical megakaryocyte-erythroid lineage bifurcation. In the bone marrow of patients with essential thrombocythemia, the MegP population was significantly expanded in the context of a high burden of Janus kinase 2 mutations. Thus, the prospectively isolatable and functionally homogeneous human MegP will be useful for the elucidation of the mechanisms underlying normal and malignant human hematopoiesis.
miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood 2009 SEP
Abstract
The role of miRNAs in regulating megakaryocyte differentiation was examined using bipotent K562 human leukemia cells. miR-34a is strongly up-regulated during phorbol ester-induced megakaryocyte differentiation, but not during hemin-induced erythrocyte differentiation. Enforced expression of miR-34a in K562 cells inhibits cell proliferation, induces cell-cycle arrest in G(1) phase, and promotes megakaryocyte differentiation as measured by CD41 induction. miR-34a expression is also up-regulated during thrombopoietin-induced differentiation of CD34(+) hematopoietic precursors, and its enforced expression in these cells significantly increases the number of megakaryocyte colonies. miR-34a directly regulates expression of MYB, facilitating megakaryocyte differentiation, and of CDK4 and CDK6, to inhibit the G(1)/S transition. However, these miR-34a target genes are down-regulated rapidly after inducing megakaryocyte differentiation before miR-34a is induced. This suggests that miR-34a is not responsible for the initial down-regulation but may contribute to maintaining their suppression later on. Previous studies have implicated miR-34a as a tumor suppressor gene whose transcription is activated by p53. However, in p53-null K562 cells, phorbol esters induce miR-34a expression independently of p53 by activating an alternative phorbol ester-responsive promoter to produce a longer pri-miR-34a transcript.
In vitro expanded cells contributing to rapid severe combined immunodeficient repopulation activity are CD34+38-33+90+45RA-. Stem cells (Dayton, Ohio) 2007 JAN
Abstract
Expansion of hematopoietic stem cells could be used clinically to shorten the prolonged aplastic phase after umbilical cord blood (UCB) transplantation. In this report, we investigated rapid severe combined immunodeficient (SCID) repopulating activity (rSRA) 2 weeks after transplantation of CD34(+) UCB cells cultured with serum on MS5 stromal cells and in serum- and stroma-free cultures. Various subpopulations obtained after culture were studied for rSRA. CD34(+) expansion cultures resulted in vast expansion of CD45(+) and CD34(+) cells. Independent of the culture method, only the CD34(+)33(+)38(-) fraction of the cultured cells contained rSRA. Subsequently, we subfractionated the CD34(+)38(-) fraction using stem cell markers CD45RA and CD90. In vitro differentiation cultures showed CD34(+) expansion in both CD45RA(-) and CD90(+) cultures, whereas little increase in CD34(+) cells was observed in both CD45RA(+) and CD90(-) cultures. By four-color flow cytometry, we could demonstrate that CD34(+)38(-)45RA(-) and CD34(+)38(-)90(+) cell populations were largely overlapping. Both populations were able to reconstitute SCID/nonobese diabetic mice at 2 weeks, indicating that these cells contained rSRA activity. In contrast, CD34(+)38(-)45RA(+) or CD34(+)38(-)90(-) cells contributed only marginally to rSRA. Similar results were obtained when cells were injected intrafemorally, suggesting that the lack of reconstitution was not due to homing defects. In conclusion, we show that after in vitro expansion, rSRA is mediated by CD34(+)38(-)90(+)45RA(-) cells. All other cell fractions have limited reconstitutive potential, mainly because the cells have lost stem cell activity rather than because of homing defects. These findings can be used clinically to assess the rSRA of cultured stem cells.
更多信息
| 种属 | Human |
|---|---|
| Contains | • Recombinant human stem cell factor (SCF) • Recombinant human interleukin 6 (IL-6) • Recombinant human interleukin 9 (IL-9) • Recombinant human thrombopoietin (TPO) |
| 配方类别 | Serum-Free |
相关产品
-
StemSpan™ SFEM用于培养和扩增造血细胞的无血清培养基
-
StemSpan™ SFEM II用于培养和扩增造血细胞的无血清培养基
